TELA Bio, Inc. TELA
We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. Our growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide.
We are dedicated to building true partnerships with surgeons and healthcare providers to deliver solutions that provide both clinical and economic improvements. We believe that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care and addresses unmet needs within the soft tissue reconstruction market.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M | $29.5M | $18.2M | $15.4M | $8.3M | $4.2M | — |
| Gross profit | $54.3M | $46.5M | $40.1M | $27.0M | $18.8M | $11.2M | $9.3M | $2.9M | $2.5M | — |
| R&D | $9.2M | $8.8M | $9.6M | $8.9M | $6.7M | $4.3M | $4.2M | $4.3M | $5.8M | — |
| SG&A | $15.7M | $14.7M | $14.9M | $13.9M | $12.5M | $10.1M | $6.2M | $4.9M | $5.0M | — |
| Total operating expenses | $88.1M | $88.2M | $84.2M | $66.1M | $48.3M | $36.5M | $28.4M | $20.7M | $19.5M | — |
| Operating income | -$33.8M | -$34.1M | -$44.1M | -$39.0M | -$29.5M | -$25.3M | -$19.2M | -$17.8M | -$16.9M | — |
| Interest expense | $5.2M | $5.3M | $5.2M | $4.1M | $3.6M | $3.6M | $3.6M | $1.8M | $4.6M | — |
| Pre-tax income | -$38.6M | -$38.0M | -$46.7M | -$44.3M | — | — | — | — | — | — |
| Income tax | $230.0K | $144.0K | — | — | — | — | — | — | — | — |
| Net income | -$38.8M | -$37.8M | -$46.7M | -$44.3M | -$33.3M | -$28.8M | -$22.4M | -$21.1M | -$21.3M | — |
| EPS, basic | -0.83 | -1.33 | -2.04 | -2.72 | -2.30 | -2.23 | -17.10 | — | — | — |
| EPS, diluted | -0.83 | -1.33 | -2.04 | -2.72 | -2.30 | -2.23 | -17.10 | -101.41 | — | — |
| Shares, diluted (wtd. avg.) | $46.9M | $28.5M | $22.9M | $16.3M | $14.5M | $12.9M | $1.8M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $50.8M | $52.7M | $47.0M | $42.0M | $43.9M | $74.4M | $45.3M | $17.3M | $11.3M | $1.5M |
| Short-term investments | — | — | — | — | — | $0 | $9.3M | — | — | — |
| Receivables | $10.3M | $10.1M | $9.7M | $6.6M | $4.2M | $2.7M | $2.8M | $1.3M | — | — |
| Inventory | $11.0M | $12.8M | $13.2M | $11.8M | $7.7M | $3.9M | $4.6M | $4.3M | — | — |
| Total current assets | $75.6M | $78.1M | $71.7M | $62.4M | $59.1M | $83.2M | $64.3M | $23.3M | — | — |
| Property, plant and equipment | $2.2M | $2.3M | $2.0M | $1.7M | $1.2M | $626.0K | $677.0K | $758.0K | — | — |
| Other intangibles | $1.4M | $1.7M | $2.1M | $2.5M | $2.3M | $2.6M | $2.9M | — | — | — |
| Total assets | $81.4M | $86.6M | $78.0M | $67.9M | $62.5M | $86.5M | $67.9M | $27.2M | — | — |
| Accounts payable | $2.3M | $2.1M | $1.7M | $1.5M | $2.4M | $652.0K | $3.2M | $3.4M | — | — |
| Total current liabilities | $18.0M | $15.6M | $17.0M | $12.4M | $10.6M | $6.6M | $6.7M | $9.6M | — | — |
| Long-term debt | $55.7M | $41.1M | $40.5M | $39.9M | $31.5M | $30.8M | $30.2M | — | — | — |
| Total liabilities | $75.1M | $58.1M | $59.2M | $53.5M | $42.4M | $37.4M | $37.0M | $40.9M | — | — |
| Retained earnings | -$397.6M | -$358.7M | -$320.9M | -$274.2M | -$229.9M | -$196.7M | -$167.9M | -$137.9M | — | — |
| Total equity | $6.3M | $28.5M | $18.9M | $14.3M | $20.1M | $49.0M | $31.0M | -$137.9M | -$108.2M | -$81.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.2M | -$41.6M | -$40.9M | -$40.7M | -$30.4M | -$24.5M | -$25.5M | -$19.9M | -$16.4M | — |
| Depreciation and amortisation | $630.0K | $632.0K | $428.0K | $383.0K | $231.0K | $221.0K | $278.0K | $463.0K | $761.0K | — |
| Stock-based compensation | $3.8M | $4.4M | $5.0M | $4.0M | $3.7M | $2.1M | $457.0K | $216.0K | $197.0K | — |
| Capital expenditure | $448.0K | $989.0K | $611.0K | $872.0K | $627.0K | $167.0K | $197.0K | $62.0K | $114.0K | — |
| Investing cash flow | $846.0K | $4.5M | -$599.0K | -$1.9M | -$627.0K | $9.1M | -$12.0M | -$1.6M | -$101.0K | — |
| Financing cash flow | $25.8M | $43.1M | $46.3M | $40.9M | $585.0K | $44.4M | $65.5M | $27.4M | $26.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-053117.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |